Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Pfizer Inc.
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
January 10, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
BEAM
PFE
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
January 05, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19
January 04, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 04, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
January 03, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
December 30, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts
December 28, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment
December 22, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
December 22, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate
December 20, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply
December 20, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
EMA Issues Advice for Potential Early Use of Pfizer’s Novel COVID-19 Oral Antiviral Candidate
December 16, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis
December 14, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death
December 14, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer to Acquire Arena Pharmaceuticals
December 13, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
ARNA
PFE
Pfizer Declares First-Quarter 2022 Dividend
December 10, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis
December 10, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older
December 09, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer and BioNTech Provide Update on Omicron Variant
December 08, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate
December 07, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 24, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
November 22, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
November 19, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis
November 18, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
November 18, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Completes Acquisition of Trillium Therapeutics
November 17, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Retirement of Chief Financial Officer Frank D’Amelio
November 17, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate
November 16, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries
November 16, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 10, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
